CROSSJECT appoints Lionel Seltz as Chief Financial Officer DIJON, France – 25 mars 2026 (06.00 PM CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), the specialty pharmaceuticals company developing emergency medicines based on its proprietary ZENEO® needle-free auto-injector platform, notably ZEPIZURE® for the emergency treatment of epileptic seizures, today announces the appointment of Lionel Seltz as Chief Financial Officer. Before joining CROSSJECT, Lionel Seltz served as CFO North Europe at Antech Diagnostics, where he led finance across several countries within a large interna...
CROSSJECT nomme Lionel SELTZ au poste de Directeur Administratif et Financier DIJON, France – 25 mars 2026 (18H00 CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), société pharmaceutique de spécialités qui développe des produits dédiés aux situations d’urgence fondés sur sa technologie propriétaire d’auto-injecteurs sans aiguille ZENEO®, en phase avancée de développement et d'enregistrement de ZEPIZURE®, un injectable pour la prise en charge des crises d'épilepsie, annonce aujourd’hui la nomination de Lionel SELTZ en qualité de Directeur Administratif et Financier. Avant de rejoind...
FY25 results: no big change. EARNINGS/SALES RELEASES The FY25 results were unsurprising, as the focus for Crossject remains on the future launch of Zeneo. The additional contribution from BARDA slightly reduces losses. However, cash consumption suggests the possibility of further dilution before achieving key operational milestones, such as the initial deliveries to BARDA. We do not anticipate significant changes to our valuation. FACT The group published its FY25 results. Operating income i...
A global footprint and diversified terminal portfolio, supported by controlled leverage, lengthening contract durations and CPI indexed terms are the backbone of Vopak's defensive business model. Current energy market turmoil may temporarily affect performance but is also increasing storage demand amid energy security concerns and the shift toward a multi fuel energy system. FID announcements should act as catalysts, while cash returns offer downside protection. Buy reiterated and TP to €56 (fro...
CROSSJECT publishes its 2025 financial results and confirms the strengthening of its operational, industrial and financial trajectory DIJON, France – 25 March 2026 (07:20 AM CET) – CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceutical company developing products for emergency situations based on its proprietary ZENEO® needle-free auto-injector technology, currently in the advanced stages of development and registration of ZEPIZURE®, an injectable for the management of epileptic seizures, today publishes its financial results for the financial year ended 31 December 2025...
CROSSJECT publie ses résultats financiers 2025 et confirme le renforcement de sa trajectoire opérationnelle, industrielle et financière DIJON, France – 24 mars 2026 (18H30 CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), société pharmaceutique de spécialités qui développe des produits dédiés aux situations d’urgence fondés sur sa technologie propriétaire d’auto-injecteurs sans aiguille ZENEO®, en phase avancée de développement et d'enregistrement de ZEPIZURE®, un injectable pour la prise en charge des crises d'épilepsie, publie aujourd’hui ses résultats financiers pour l’exercice ...
In this ING equities impact assessment of the situation in the Middle East report, we focus on a selection of 11 companies which we cover and we expect to be impacted by the current situation in the Middle East following the war in Iran, which started on 28 February and has since spread further into the region. We found that every company in this report faces its own challenges in the short term, while we also discuss the longer-term strategic implications.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.